Data from a consecutive series of 13 patients with stage III malignant melanoma indicate that patients with BRAFV600E-mutant marginally resectable or irresectable melanoma are able to derive clinical benefit from neoadjuvant BRAF inhibition. This approach enabled all patients to undergo surgical resection, which was macroscopically successful in all cases. A total of four patients had a complete pathological response with no viable tumour cells detected in resection specimens, and 10 patients remain free of disease after a median follow-up duration of 20 months.